## Franziska Scheibe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6593938/publications.pdf

Version: 2024-02-01

687363 839539 1,649 19 13 18 citations h-index g-index papers 19 19 19 3228 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Daratumumab for treatmentâ€refractory antibodyâ€mediated diseases in neurology. European Journal of Neurology, 2022, 29, 1847-1854.	3.3	28
2	Decline in the number of patients with meningitis in German hospitals during the COVID-19 pandemic. Journal of Neurology, 2022, 269, 3389-3399.	3.6	12
3	Intravenous immunoglobulins for treatment of severe COVID-19-related acute encephalopathy. Journal of Neurology, 2022, 269, 4013-4020.	3.6	6
4	Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nature Neuroscience, 2021, 24, 168-175.	14.8	991
5	Novichok nerve agent poisoning. Lancet, The, 2021, 397, 249-252.	13.7	85
6	Isoflurane in (Super-) Refractory Status Epilepticus: A Multicenter Evaluation. Neurocritical Care, 2021, 35, 631-639.	2.4	15
7	Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died. JAMA Neurology, 2021, 78, 948.	9.0	106
8	Acute porphyrias – A neurological perspective. Brain and Behavior, 2021, 11, e2389.	2.2	15
9	Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis. Journal of Neurology, 2020, 267, 317-323.	3.6	43
10	Movement disorders after hypoxic brain injury following cardiac arrest in adults. European Journal of Neurology, 2020, 27, 1937-1947.	3.3	10
11	Withholding or withdrawing life support in long-term neurointensive care patients: a single-centre, prospective, observational pilot study. Journal of Medical Ethics, 2020, , medethics-2019-106027.	1.8	O
12	Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1618-1632.	3.0	32
13	Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e479.	6.0	13
14	Affinities of human NMDA receptor autoantibodies: implications for disease mechanisms and clinical diagnostics. Journal of Neurology, 2018, 265, 2625-2632.	3.6	32
15	Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology, 2017, 88, 366-370.	1.1	162
16	Devastating humoral CIDP variant remitted by autologous stem cell transplantation. European Journal of Neurology, 2016, 23, e12-4.	3.3	13
17	Neurosarcoidosis: Correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity. Journal of the Neurological Sciences, 2013, 335, 124-130.	0.6	70
18	Diagnostic pitfalls: a case of neurosarcoidosis mimicking tuberculous meningitis. Journal of Neurology, 2012, 259, 1736-1739.	3.6	6

#	Article	IF	CITATIONS
19	Parainfectious myelitis associated with parvovirus B19 infection. Journal of Neurology, 2010, 257, 1557-1558.	3.6	10